Stent graft for nephrologists: Concerns and consensus

Loay Salman, Arif Asif

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The role of the stent graft is emerging in the management of arteriovenous dialysis access. Physicians are incorporating this device in the management of three distinct problems - vein-graft anastomotic stenosis, pseudoaneurysm formation, and cephalic arch stenosis - with varying degrees of success. Indeed, a recent randomized, controlled trial to evaluate the role of angioplasty plus stent graft versus angioplasty alone for the management of stenosis at the vein-graft anastomosis led to the approval of the stent graft by the Food and Drug Administration; however, several elements of the management of stenosis at the vein-graft anastomosis/cephalic arch as well as the repair of pseudoaneurysms by stent graft remain controversial. The situation is further complicated and warrants a cost-to-benefit ratio analysis when the added cost of the device is appended to the procedure. In contrast to the controversies, angioplasty-induced complete vascular rupture is one situation in which a stent graft is indicated beyond any doubt. With recent conditional Food and Drug Administration approval, it is anticipated that the use of stent grafts might increase in our patients. In this context, it is critically important that nephrologists be familiar with the current controversies and consensus that surround the use of stent grafts for dialysis access. Just as therapeutic interventions are analyzed in other disciplines within nephrology, these experts must appraise the use of this device for dialysis access. This report presents an up-to-date synopsis on the use of the stent graft that would assist renal physicians in requesting or rejecting the device for the optimal management of their patient's vascular access dysfunction.

Original languageEnglish
Pages (from-to)1347-1352
Number of pages6
JournalClinical Journal of the American Society of Nephrology
Volume5
Issue number7
DOIs
StatePublished - Jul 1 2010

Fingerprint

Stents
Transplants
Pathologic Constriction
Angioplasty
Dialysis
Veins
Equipment and Supplies
False Aneurysm
United States Food and Drug Administration
Blood Vessels
Nephrologists
Head
Physicians
Drug Approval
Nephrology
Cost-Benefit Analysis
Rupture
Randomized Controlled Trials
Kidney
Costs and Cost Analysis

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

Stent graft for nephrologists : Concerns and consensus. / Salman, Loay; Asif, Arif.

In: Clinical Journal of the American Society of Nephrology, Vol. 5, No. 7, 01.07.2010, p. 1347-1352.

Research output: Contribution to journalArticle

Salman, Loay ; Asif, Arif. / Stent graft for nephrologists : Concerns and consensus. In: Clinical Journal of the American Society of Nephrology. 2010 ; Vol. 5, No. 7. pp. 1347-1352.
@article{a2da70530ff6470db82c927d85c90ef6,
title = "Stent graft for nephrologists: Concerns and consensus",
abstract = "The role of the stent graft is emerging in the management of arteriovenous dialysis access. Physicians are incorporating this device in the management of three distinct problems - vein-graft anastomotic stenosis, pseudoaneurysm formation, and cephalic arch stenosis - with varying degrees of success. Indeed, a recent randomized, controlled trial to evaluate the role of angioplasty plus stent graft versus angioplasty alone for the management of stenosis at the vein-graft anastomosis led to the approval of the stent graft by the Food and Drug Administration; however, several elements of the management of stenosis at the vein-graft anastomosis/cephalic arch as well as the repair of pseudoaneurysms by stent graft remain controversial. The situation is further complicated and warrants a cost-to-benefit ratio analysis when the added cost of the device is appended to the procedure. In contrast to the controversies, angioplasty-induced complete vascular rupture is one situation in which a stent graft is indicated beyond any doubt. With recent conditional Food and Drug Administration approval, it is anticipated that the use of stent grafts might increase in our patients. In this context, it is critically important that nephrologists be familiar with the current controversies and consensus that surround the use of stent grafts for dialysis access. Just as therapeutic interventions are analyzed in other disciplines within nephrology, these experts must appraise the use of this device for dialysis access. This report presents an up-to-date synopsis on the use of the stent graft that would assist renal physicians in requesting or rejecting the device for the optimal management of their patient's vascular access dysfunction.",
author = "Loay Salman and Arif Asif",
year = "2010",
month = "7",
day = "1",
doi = "10.2215/CJN.02380310",
language = "English",
volume = "5",
pages = "1347--1352",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "7",

}

TY - JOUR

T1 - Stent graft for nephrologists

T2 - Concerns and consensus

AU - Salman, Loay

AU - Asif, Arif

PY - 2010/7/1

Y1 - 2010/7/1

N2 - The role of the stent graft is emerging in the management of arteriovenous dialysis access. Physicians are incorporating this device in the management of three distinct problems - vein-graft anastomotic stenosis, pseudoaneurysm formation, and cephalic arch stenosis - with varying degrees of success. Indeed, a recent randomized, controlled trial to evaluate the role of angioplasty plus stent graft versus angioplasty alone for the management of stenosis at the vein-graft anastomosis led to the approval of the stent graft by the Food and Drug Administration; however, several elements of the management of stenosis at the vein-graft anastomosis/cephalic arch as well as the repair of pseudoaneurysms by stent graft remain controversial. The situation is further complicated and warrants a cost-to-benefit ratio analysis when the added cost of the device is appended to the procedure. In contrast to the controversies, angioplasty-induced complete vascular rupture is one situation in which a stent graft is indicated beyond any doubt. With recent conditional Food and Drug Administration approval, it is anticipated that the use of stent grafts might increase in our patients. In this context, it is critically important that nephrologists be familiar with the current controversies and consensus that surround the use of stent grafts for dialysis access. Just as therapeutic interventions are analyzed in other disciplines within nephrology, these experts must appraise the use of this device for dialysis access. This report presents an up-to-date synopsis on the use of the stent graft that would assist renal physicians in requesting or rejecting the device for the optimal management of their patient's vascular access dysfunction.

AB - The role of the stent graft is emerging in the management of arteriovenous dialysis access. Physicians are incorporating this device in the management of three distinct problems - vein-graft anastomotic stenosis, pseudoaneurysm formation, and cephalic arch stenosis - with varying degrees of success. Indeed, a recent randomized, controlled trial to evaluate the role of angioplasty plus stent graft versus angioplasty alone for the management of stenosis at the vein-graft anastomosis led to the approval of the stent graft by the Food and Drug Administration; however, several elements of the management of stenosis at the vein-graft anastomosis/cephalic arch as well as the repair of pseudoaneurysms by stent graft remain controversial. The situation is further complicated and warrants a cost-to-benefit ratio analysis when the added cost of the device is appended to the procedure. In contrast to the controversies, angioplasty-induced complete vascular rupture is one situation in which a stent graft is indicated beyond any doubt. With recent conditional Food and Drug Administration approval, it is anticipated that the use of stent grafts might increase in our patients. In this context, it is critically important that nephrologists be familiar with the current controversies and consensus that surround the use of stent grafts for dialysis access. Just as therapeutic interventions are analyzed in other disciplines within nephrology, these experts must appraise the use of this device for dialysis access. This report presents an up-to-date synopsis on the use of the stent graft that would assist renal physicians in requesting or rejecting the device for the optimal management of their patient's vascular access dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=77954801657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954801657&partnerID=8YFLogxK

U2 - 10.2215/CJN.02380310

DO - 10.2215/CJN.02380310

M3 - Article

C2 - 20507955

AN - SCOPUS:77954801657

VL - 5

SP - 1347

EP - 1352

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 7

ER -